Although much effort has been directed toward the improvement of the chemotherapy for schistosomiasis mansoni, and despite the large progress obtained in this field, curative treatment of this disease with the already known standard antischistosomal compounds presents some difficulties. The high price of drugs, drug side effects, cases of drug resistance, among other problems, point toward the continuous search for new active substances.
Coelho and Pereira4 showed a promising activity of 9-acridanone-hydrazone compounds in Cebus monkeys experimentally infected with the LE strain of Schistosoma mansoni.
However, a question arises whenever new promising compounds against schistosomiasis appear. Are they effective against all human schistosomiasis, and even if active against a strain of a specific species (S. mansoni, for instance), can their effectiveness be extended to other strains? It is well known that S. mansoni, mainly in some countries of Africa, presents different suscep tibilities to chemotherapy with oxamniquine, via oral route. Thus, in Brazil and West Africa, 15mg/kg body weight is the dosage commonly used, whereas in East Africa the effective dose ranges from 30 to 45mg/kg, and in Egypt doses of up to 60mg/kg given over three days are required16. On the other hand, the resistance against oxamniquine by S. m ansoni has been detected in Brazilian patients16. Cioli et al3 clearly showed that this resistance was controlled by a single autosomal recessive gene.
In Brazil, three species of Biom phalaria mollusks are responsible for the natural transmission of schistosomiasis mansoni, and these species are predominant as vectors in different areas. Thus, the adaptation between some strains of the parasite and the geographical strains of snails2 81011 has been demonstrated, as well as the variation in the pathogenicity degree related to strains of S. m ansoni has been proved51315.
The purpose of the present work, using the Cebus monkey model, is to verify whether the 
MATERIAL AND METHODS
Capuchin monkeys ( Cebus sp), adults of both sexes, were maintained in individual cages in the animal house. The monkeys were fed on daily with bred soaked in milk, fruit, and standard pellet food. They were infected with about 200 cercariae of S. mansoúi (SJ strain), transcutaneously. The life cycle of the trematode was maintained at the laboratory through hamster -Biomphalaria tenagophilahamster passages. Acridanone-hydrazone drugs were given after the mature infection had been stablished. The monkeys that were found to be positive (presenting large numbers of schistosome eggs in the stools and in rectal snips) were selected for the experiments. The compounds Ro-15-5458/000, Ro-15.8843/000, Ro-15.9268/000 and Ro-16.2308/000 ( Figure 1 ) were administered at the dosage o f 12.5mg/kg body weight, by oral route, single dose. The infected monkey E-2 was kept as control. The quantitative oogram of rectal snips9, stool examination4, and perfusion of portal system for worm recoveryl2 were used as criteria for determination of parasitological cure.
RESULTS
It must be emphasized that the coproscopies performed confirmed the oogram in rectal snips in all cases.
The drug effects against the SJ strain of S. mansoni are summarized in Table 1 . The stool examination and perfusion o f portal system of the monkeys confirmed the findings obtained with the rectal snips. So, when all the treated monkeys were examined (26 examinations per monkey) no eggs could be detected in stool examinations. On the other hand, the presence of viable eggs was detected in all the stool examinations of the control monkey. No worms could be detected through perfusion into the treated monkeys, whereas 83 worms (24 females and 59 males) were recovered from the control monkey (E-2).
DISCUSSION
Some 9-acridanone-hydrazones have been proved very effective in the preclinical treatment for schistosomiasis, when nonhuman Tropical 28:179-183, jul-set, 1995. primate models, as baboons14 and Cebus monkeys4, were used. Very good results have been reported by Coelho and Pereira4 using Cebus monkeys infected with the LE strain of S. mansoni, and treated with some acridanonehydrazones that showed curative activity at doses as low as 25mg, sometimes 12.5mg, per os, single administration. These authors showed that the results obtained through periodical rectal biopsies and stool examinations carried out prior and up to six months after treatment were really curative. In some cases, some treated simians (negative for coproscopies and rectal biopsies) were sacrificed at that time, and few or no worms could be found after the portal system perfusion, thus showing that the laboratory findings were not due to chemical sterilization o f the worms but, in fact, were associated with the consequent death of the parasites. In that -183, jul-set, 1995. occasion, it was verified that the curative doses, besides being quite low, and singly orally administered, did not show visible side effects on the primates. In the same work, it has been observed a marked activity of all the compounds studied against the SJ strain of S. mansoni, at a lower dose (12.5mg/kg), thus confirming the results obtained by Coelho and Pereira4 with the LE strain. These results lead the authors to think on the possibility of the same compounds being successful in a lower curative dose (less than 12.5mg/kg body weight in Cebus monkeys). It is well known that many schistosomicides in the monkey require near five times more dosing than that used for man. Thus it seems that doses lower than 3mg/kg body weight could possibly be used for man, although it must be proved whether the toxicity of these compounds does not prevent their use in humans.
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The report on drug resistance related to the use of oxamniquine, the most utilized drug in the treatment for schistosomiasis in Brazil17, widen the possibility of considering the drugs here studied as an important reserve supply to be used, perhaps, in the near future. 
RESUMO
